GeneDec 6, 2025

New CRISPR tools for editing gene activity, RNA, and improving molecular tests

CRISPR Gene Editing Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 3, 2026

Abstract

CRISPR 2.0 encompasses a diverse range of genome editing tools, including dCas9-based epigenetic effectors and RNA-targeting systems.

The review summarizes mechanisms and advances in CRISPR technologies, such as DNA base editors and prime editors.
A comparison of various genome editing approaches highlights differences in effectiveness and applications, including RNAi and Cas13 methods.
Practical considerations such as delivery technologies, safety concerns, and regulatory pathways are evaluated across different CRISPR applications.
Case studies link laboratory evidence to potential clinical outcomes, indicating the translational readiness of certain CRISPR tools.
Technologies are classified based on their readiness for clinical use, with diagnostics and some ex-vivo therapies nearing implementation.

Simplified

Non-canonical CRISPR systems adaptation has led to genome editing through nucleases, and the development of transcriptional and epigenetic regulation, transcriptome editing, and molecular diagnostics has resulted in a diversified set of tools-CRISPR 2.0. In this review, the author summarizes the mechanisms and recent engineering advances of (i) dCas9-based epigenetic effectors, (ii) RNA-targeting Cas13 systems and engineered RNA editors, (iii) DNA base editors and prime editors, and (iv) CRISPR-powered diagnostic platforms and their translational readiness. There is a critical comparison of the various approaches (e.g., RNAi/ASO versus Cas13-based methods; base editing versus prime editing) along with practical translational considerations such as delivery technologies, safety (off-target/edit windows, mosaicism), and regulatory pathways which are evaluated. Three concise case studies refer to map laboratory evidence to clinical or near-clinical outcomes and the ethical and governance discussion is widened to include global access, intellectual property and equity in deployment. Finally, the authors classify technologies according to their level of readiness - diagnostics and some ex-vivo therapeutic approaches are already in or very close to clinical use, chosen in-vivo editing methods are undergoing early trials, and AI-assisted nuclease design is still mostly theoretical but is getting better fast. This comprehensive viewpoint is intended to help researchers and physicians understand which CRISPR tools are most likely to be translated soon and where more validation is required.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The author is an employee of Strand Life Sciences. Strand Life Sciences is a genomics-based research and diagnostics company that combines a long track record in bioinformatics with cutting-edge laboratory assays and a vast hospital partner network to drive newer generations of patient care. This manuscript was prepared independently by the author. No proprietary data, internal analyses, or editorial input from Strand Life influenced the preparation or content of this review. The views expressed are those of the author alone. The author declares no financial gain from the publication of this work and no other competing interests.

PubMed

New CRISPR tools for editing gene activity, RNA, and improving molecular tests

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the crispr gene editing brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the crispr gene editing brief